Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bavencio Review Timeline And Reviewers

Executive Summary

Overview of development timeline and review team for EMD Serono’s Bavencio (avelumab) for metastatic Merkel cell carcinoma.

You may also be interested in...



Real-World Evidence At US FDA: Bavencio, Blincyto Approvals Point Way Toward Broader Use

Breakthrough-designated oncologics used historical comparator data to determine efficacy threshold for pivotal Phase II studies supporting accelerated approval; Blincyto’s subsequent full approval offers validation with conventional controlled study. 

Keeping Track: US FDA Clears On Target’s Cytalux, VBI’s PreHevbrio; Keytruda Grows In Adjuvant Melanoma

The latest FDA approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Bad Times For Breakthrough Drugs Targeting Chemo Complications; Submissions From BMS, Merck

The latest news about applications under FDA review, from the Pink Sheet’s US FDA Performance Tracker

Topics

Related Companies

UsernamePublicRestriction

Register

PS123646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel